The possible ameliorative role of mesenchymal stem cells and curcumin on the lung in experimentally induced type I diabetes: Histological and immunohistochemical study

Amany Elsayed Mohammed Hamoud1, Hala Gabr Metwally2

Departments of 1Anatomy and Embryology and 2Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

ABSTRACT

Background: Type 1 diabetes mellitus affects lungs due to poor glycemic control. Improvement in both lung function and architecture in experimentally-induced lung injury that received exogenous AMSCs by different mechanisms was found. Curcumin has a potent antioxidant and antifibrotic function.

Objective: The current study was designed to elucidate the possible ameliorative role of mesenchymal stem cells and curcumin on the lung in experimentally induced type I diabetes by histological and immunohistochemical study.

Materials and Methods: Twenty six adult albino rats were divided into five groups: donor, control group, curcumin group and adipose derived mesenchymal stem cell (AMSCs) group. Group II (diabetic group) received a single dose STZ 50 mg/kg/day, group III received STZ and powdered diet supplemented with 0.05% curcumin, group IV received STZ and 1x106 of cultured and labelled rat AMSCs. Lung sections were subjected to histological, morphometric, biochemical and statistical studies.

Results: Diabetes induced histological changes in lung in the form of inflammatory changes in bronchiole, a sig increase in the thickness of interalveolar septa, thickness of the vessels wall, area % of collagen and count CD105+ve cells. Sig decrease in antioxidant activity and sig increase in oxidant enzymes. Sig increase in L-hydroxyproline(L-hyp) level as well STAT and SMAD genes. Administration of curcumin and AMSCs improved sig the previous changes.

Conclusion: Diabetes induced lung injuries in rats that was ameliorated by by curcumin, but AMSCs have more pronounced effect than curcumin therapy.

Key Words: ADMSCs, antioxidant, curcumin, diabetes, lung.

INTRODUCTION

Type 1 diabetes mellitus affects many organs, including heart, lung, kidney, retina, liver, and skeletal muscle due to poor glycemic control. The exact mechanism of lung affection (either fibrotic or inflammatory lesion) in diabetic patients remain unclear[1].

Pancreatic islet transplantation is an excellent option for treatment of patient with uncontrolled hypoglycaemia despite of insulin treatment, however this approach is inaccessible due to limited donors and the adverse side effect of life-long immunosuppressive treatment[2].

Stem cells are highly specialized cells and the most promising therapies in many tissues regeneration as they are easy to differentiate into a number of cell types that make up the body tissues and organs. Mesenchymal stem cells (MSCs) can be isolated and expanded with high efficiency from several adult and foetal tissues including bone marrow, adipose tissue, dental pulp and umbilical cord blood[3].

Different studies have used streptozotocin (STZ) to induce type I diabetes mellitus in laboratory animals. The single diabeticogenic dose of STZ has been documented in different studies from 50 mg/kg b/w up to 70 mg/kg. The cytotoxic action of STZ is mediated by reactive oxygen species[4].

The improvement in both lung function and architecture in experimentally-induced lung injury in either animal models that received exogenous MSCs or MSC-conditioned media might have different mechanisms. Adipose-derived mesenchymal stem cells (AMSCs) play a potential role in stem cell transplantation in animal models[5].
Curcumin is a potent antioxidant as it protects against streptozotocin-induced oxidative stress by scavenging free radicals, well-known anti-inflammatory, antimicrobial, antiproliferative as well as anti-atherosclerotic effects. Also, its antifibrotic role in liver, kidney and lung of experimental animal has been documented[9].

The aim of the present study was to elucidate the possible ameliorative role of AMSCs and curcumin on the lung in induced type I diabetes mellitus in adult male rats.

**PATIENTS AND METHODS**

**Animals:**

The current study was carried out on 26 adult male albino rats aged three to five months and weighing about 180-230 grams were used in this study. The rats were obtained from Animal House of Kasr-Alainy, Faculty of Medicine, Cairo University. Rats were housed for one week for environmental adaptation under standard laboratory conditions at 22-24 °C with 12 hours light/dark cycle. They were fed on a constant adequate nutrition diet and allowed free access to drinking water ad libitum. The experimental work was conducted in accordance with the guidelines of the animals committee at Cairo University. They were housed in cages, six rats/cage. The rats were divided into five groups as follow (six rats each):

- **Donor Group:** Two rats were used for stem cell isolation, culture, phenotyping and labeling.

- **Group I (Control group):** Two rats received a single intraperitoneal (IP) injection of 0.5 ml citrate buffer, two rats received 1 ml PBS intravenously, and two rats received powdered diet supplemented with 0.05% curcumin.

- **Group II (Diabetic group):** Received a single dose of STZ (Sigma Company, St. Louis, Mo, USA) in a powder form as 1 g vial in a dose of 50 mg/kg/day dissolved in 0.5 ml sodium citrate buffer IP for each rat. Three days following STZ injection, diabetes was confirmed by measuring the blood glucose level. The animals were considered diabetic if their blood glucose levels were higher than 200 mg/dl[10]. The animals were sacrificed four weeks following diabetes confirmation.

- **Group III (Curcumin group):** Rats were subjected to diabetes induction as in group II, on the day following confirmation of diabetes, they received their powdered diet supplemented with 0.05% curcumin (w/w). The animals were sacrificed four weeks following curcumin administration[10].

- **Group IV (AMSCs Group):** Rats were subjected to diabetes induction as in group II, on the day following diabetes confirmation, 1 x 106 of cultured and labelled rat AMSCs, suspended in 1 ml PBS, were injected into the tail vein on two successive days. Then the animals were sacrificed after four weeks[9].

**Methods:**

All rats were sacrificed by cervical dislocation[10] using IP injection of phenobarbitone sodium (60 mg/kg)[11]. Central ventral midline incision was performed for each animal. The lung were removed and sections were fixed in 10% formal saline for 48 hours. Paraffin blocks and 5μm thick sections were prepared. Sections were subjected to:

- **Histological study:** Haematoxylin and Eosin (H&E) stain[12] and Masson’s trichrome stain[13].

- **Histochemical study:** Sections were stained with Prussian blue (PB) stain for demonstration of iron oxide labelled therapeutic stem cells (SCs)[14].

- **Immunohistochemical study:** CD105 immuno staining is the marker for MSCs. 0.1 ml prediluted primary antibody (CD105) rabbit polyclonal Ab (ab27422) that incubated at room temperature in moist chamber for 30-60 minutes. Tonsils were used as positive control specimens. Cellular localization is the cell membrane. One of the lung sections was used as a negative control by passing the step of applying the primary antibody[13].

- **Morphometric study:** Thickness of the alveolar septa and the thickness of pulmonary vessels (indicated by the distance parameter) were measured in H&E stained sections. The area percentage of collagen fibers were done in Masson’s trichrome sections. The count of CD105 +ve cells were assessed using interactive measurements menu. These measurements were done in 10 high power fields (HPF) in control and experimental groups.

**Chemical parameters:**

A. Oxidative and antioxidative parameters: Measurement of malanodialdehyde (MDA), glutathione (GSH) and catalase (CAT) activity: Half of the specimens were kept in the deep freezer for homogenization. 1gm of specimen was homogenized in 10 ml normal saline by using homogenizer (Ortoalresa, Spain). Then centrifuged at 1000 X g for about 10 minutes. It was collected in and kept in the deep freezer (at - 20°C) reduced GSH, CAT and MDA[16].

B. Tumor necrosis factora (TNF-α): Quantitative determination in lung homogenate, was measured by use of TNF-α ELISA kit (R&D Systems, Inc., USA) according to the manufacturers’ manual[17].

C. Hydroxyproline (L-hyp): L-hyp content was quantified colorimetrically from lung tissue homogenate samples by using the chloramine T method[18].
AMSCs were labelled by incubation with ferumoxides injectable solution (25 microgram Fe/ml, Feridex, Berlex Laboratories) in culture medium. The adherent cells were expanded by serial passages, and ADMSCs from 3 to 5 passages were used.

2. Labelling: AMSCs were labelled by incubation with ferumoxides injectable solution (25 microgram Fe/ml, Feridex, Berlex Laboratories) in culture medium for 24 hours with 375 nanogram/ml poly L lysine that was added one hour before the incubation. Then it was assessed histologically using Prussian blue. Feridex labelled AMSCs were washed in PBS, trypsinized, washed and resuspended in 0.01 Mol/L PBS at concentration of 1×1,000,000 cells/ml[23].

3. Viability: Was done using trypan blue dye exclusion test. This method is based on that the viable cells do not accept certain dyes, while dead cells receive[23].

4. Flow cytometry: Flow cytometric analyses were performed on a Fluorescence Activated Cell Sorter (FACS) flow cytometer (Coulter Epics Elite, Miami, FL, USA). MSCs were trypsinized and washed twice with PBS. A total number of 1 ×105 HMSC were used for each run. To evaluate the MSCs marker profile, cells were incubated in 100 μL of PBS with 3 μL of CD105-FITC for 20 min at room temperature. Antibody concentration was 0.1 mg mL-1[24]. Cells were washed twice with PBS and finally diluted in 200 μL of PBS. The expression of surface marker was assessed by the mean fluorescence. CD105 (MSCs marker). The percentage of cells positive for CD 105 was determined by subtracting the percentage of cells stained non-specifically with isotype control antibodies.

**Mesenchymal stem cells preparation:**

1. Adipose derived mesenchymal stem cells (AMSCs) isolation and culture[20]: The precipitate was resuspended and plated onto a cell culture dish (Corning, NY, USA) at a density of 105 cells/ml in fresh Dulbecco's modified Eagle's medium (DMEM)/F-12 (Invitrogen) supplemented with 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). Cell cultures were maintained in a standard humidified incubator, saturated by 5% CO2, at 37 °C. Twenty four hours later, the nonadherent cells were eliminated by changing the culture medium. The adherent cells were expanded by serial passages, and ADMSCs from 3 to 5 passages were used.

2. Labelling: AMSCs were labelled by incubation with ferumoxides injectable solution (25 microgram Fe/ml, Feridex, Berlex Laboratories) in culture medium for 24 hours with 375 nanogram/ml poly L lysine that was added one hour before the incubation. Then it was assessed histologically using Prussian blue. Feridex labelled AMSCs were washed in PBS, trypsinized, washed and resuspended in 0.01 Mol/L PBS at concentration of 1×1,000,000 cells/ml[23].
diabetic rats treated with AMSCs showed a bronchiole with few shed epithelial cells, a congested arteriole and a congested venule (Plate.2b). Closer observation revealed apparently normal alveoli and alveolar sacs lined by numerous pneumocytes type I (Plate.2c).

- **Masson’s trichrome stained sections**: Section in the lung of a control rat showed fine collagen fibers in the interalveolar septa. While, the collagen fibers were increased in the diabetic group with thickening in the interalveolar septa. In the lung of a diabetic rat treated with curcumin showed less collagen fibers in the interalveolar septa. In the lung of a diabetic rat treated with AMSCs fine collagen fibers were found in the interalveolar septa and around pulmonary capillaries (Plate 3. a,b,c,d).

- **Prussian blue stained sections**: Section in the lung of a control rat, diabetic and adiabetic rat treated with curcumin showed negative staining among alveoli and alveolar sacs. But in the lung of a diabetic rat there was thickening in the interalveolar septa. Section in the lung of a diabetic rat treated with AMSCs showed +ve staining of spindle cells among alveoli, alveolar sacs and minimally thickened interalveolar septa (Plate 4.a,b,c,d).

- **CD105 immunostaining staining sections**: Section in the lung of a control rat showed negative IE. Section in the lung of a diabetic rat showed few CD105+ve spindle cells in thickened interalveolar septa. Section in the lung of a diabetic rat treated with curcumin showed some CD105+ve spindle cells in less thickened interalveolar septa. Section in the lung of a diabetic rat treated with SCs showed multiple CD105+ve spindle cells in minimally thickened interalveolar septa (Plate 5.a,b,c,d).

**Morphometric Results:**

- **Thickness of the interalveolar septa**: By the application of two way ANOVA test, results of the mean thickness (µ) of the interalveolar septa in haematoxylin and eosin stained sections was studied in different experimental groups. A sig increase (P<0.05) was found in the diabetic group compared to control, curcumin and SC therapy group. In addition a sig decrease was detected in curcumin compared to diabetic group, and in AMSCs group compared to curcumin and diabetic groups (Table 2).

- **Thickness of the wall of the vessels of the lung**: In the control group, the mean thickness (µ) of the wall of the pulmonary vessels measured in haematoxylin and eosin stained sections. The mean thickness assessed indicated a sig increase (P<0.05) in diabetic group compared to the other groups and in curcumin group compared to control and AMSCs groups (Table 2).

- **Area % of collagen fibers**: In control group, the mean area % of collagen fibers found in the interalveolar septa was measured by examination of Masson’s trichrome stained sections. The values recorded indicated a sig increase (P<0.05) in diabetic group compared to the other groups and in curcumin group compared to control and AMSCs groups (Table 2).

- **Count of CD 105+ve cells**: In diabetic group, the mean count of CD105+ve cells found was assessed by examination of immune-stained sections. The mean values indicated a sig increase (P<0.05) in AMSCs group compared to the other two groups and in curcumin group compared to diabetic group (Table 2).

**Chemical changes results:**

- **Oxidative and antioxidative parameter changes**: In diabetic group, GSH and CAT values were sig decreased compared to the other groups, while, MDA was sig increased. In curcumin group a sig decrease was found in MDA value and a sig increase was detected in CAT and GSH values compared to the diabetic group. On the other hand, in AMSCs group a sig decrease was found in MDA value and a sig increase was detected in CAT and GSH values compared to the diabetic and curcumin groups.

- **SMAD and STAT genes**: Sig increase was found in both STAT and SMAD genes in diabetic group compared to the other groups. While, a sig decrease was found in curcumin group compared to diabetic group, and in AMSCs group compared to diabetic and curcumin groups.

- **TNF α and L-hyp**: Sig increase was found in both TNF α and L-hyp in diabetic group compared to other groups. While, a sig decrease was evident in AMSCs group compared to diabetic and curcumin groups (Table 3).
Table 1: The primer sequence of the studied SMAD and STAT gene

<table>
<thead>
<tr>
<th>Primer sequence</th>
<th>SMAD</th>
<th>Forward: 5'-AAATGACAGCAGCAGGGACACTA-3'.</th>
<th>Reverse: 5'-TGAGGAGGTAGGACCCACAGTGA-3'.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>STAT</td>
<td>Forward: 5'-TGGAAGAGGCGGCAGCATAGC-3'.</td>
<td>Reverse: 5'CACGGCCCCCATTCCCCACAT-3'.</td>
</tr>
</tbody>
</table>

Table 2: Mean ± standard deviation (SD) of the thickness of interalveolar septa (IAS), thickness of the wall of pulmonary vessels (T), area % of collagen fibers (CF) and count of CD 105 +ve cells in different groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Thickness of IAS</th>
<th>T of wall of pulmonary vessels</th>
<th>Area % of CF</th>
<th>Count of CD105 +ve cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>23.37±3.93</td>
<td>4.08±0.86</td>
<td>1.18±0.21</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Diabetic group</td>
<td>106.73±7.39*</td>
<td>35.59±0.97*</td>
<td>24.13±3.46*</td>
<td>6.18±0.21*</td>
</tr>
<tr>
<td>Curcumin group</td>
<td>55.57±3.83^</td>
<td>18.90±2.02^</td>
<td>4.18±1.08^</td>
<td>11.13±3.46^</td>
</tr>
<tr>
<td>AMSCs group</td>
<td>29.97±3.13#</td>
<td>7.40±13.23#</td>
<td>2.72±0.45#</td>
<td>20.18±1.08#</td>
</tr>
</tbody>
</table>

* sig compared to all groups.
^ sig compared to diabetic group.
# sig compared to diabetic and curcumin groups.

Table (3): Mean change in oxidative, STAT, SMAD genes, TNFα and l-hyp in different groups

<table>
<thead>
<tr>
<th>Group</th>
<th>MDA</th>
<th>GSH</th>
<th>CAT</th>
<th>STAT</th>
<th>SMAD</th>
<th>TNF α</th>
<th>L-hyp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>10.8±1.35</td>
<td>78.3±20.5</td>
<td>110.8±30.87</td>
<td>1.00±0.3</td>
<td>1.05±0.2</td>
<td>12.9±3.2</td>
<td>25.8±7.3</td>
</tr>
<tr>
<td>Diabetic</td>
<td>36.0±5.2*</td>
<td>32.7±8.3*</td>
<td>58.8±14.4*</td>
<td>5.45±1.5*</td>
<td>5.67±2.1*</td>
<td>78.9±20.4*</td>
<td>68.5±19.4*</td>
</tr>
<tr>
<td>Curcumin</td>
<td>18.7±2.71^</td>
<td>55.3±14.4^</td>
<td>82.5±25.54^</td>
<td>2.43±1.3^</td>
<td>2.81±0.6^</td>
<td>33.6±10.1^</td>
<td>42.5±12.45^</td>
</tr>
<tr>
<td>AMSCs</td>
<td>12.2±1.96#</td>
<td>70.6±20.67#</td>
<td>100.4±35.23#</td>
<td>1.25±0.3#</td>
<td>1.30±0.3#</td>
<td>16.2±4.34#</td>
<td>29.4±7.6#</td>
</tr>
</tbody>
</table>

* sig compared to all groups.
^ sig compared to diabetic group.
# sig compared to diabetic and curcumin groups.
Plate (1): a) section in the lung of a control rat showing two bronchioles (B), a venule (v), alveoli (a), alveolar sacs (A)(H&E, x 100). b) section in the lung of a control rat showing alveoli (a), alveolar sacs (A) lined mainly by pneumocytes type I (p) and interalveolar septa (I) exhibiting pulmonary capillaries (c)(H&E, x 400). c) section in the lung of a diabetic rat showing a small bronchiole with partially obliterated lumen by multiple shed cells (*) and surrounded by dense infiltration (arrowhead). Some shed epithelial cells (arrow) are seen in the lumen of a part of another bronchiole (H&E, x 100). d) section in the lung of a diabetic rat showing thickening of the interalveolar septa (*). Note a congested vessel (arrow) and another vessel with thickened wall (arrowhead)(H&E, x 100). e) section in the lung of a diabetic rat showing mononuclear infiltrating cells including fibroblasts (arrowheads) and thickened interalveolar septa (i)(H&E, x 400). f) section in the lung of a diabetic rat treated with curcumin showing less thickening of interalveolar septa (*). Note partial wall thickening of a vessel (arrow) (H&E, x 100).

Plate (2): a) section in the lung of a diabetic rat treated with curcumin showing less dense infiltrating cells (arrowhead) in the interalveolar septa. Note normal alveoli (a) and alveolar sacs (A) lined by multiple pneumocytes type I (p)(H&E, x 400). b) section in the lung of a diabetic rat treated with SCs in showing a bronchiole with few shed epithelial cells (*), a congested arteriole (arrow) and a congested venule (arrowhead)(H&E, x 100). c) Section in the lung of a diabetic rat treated with SCs showing apparently normal alveoli (a) and alveolar sacs (A) lined by numerous pneumocytes type I (p)(H&E, x 400).
Plate (3): a) section in the lung of a control rat showing fine collagen fibers (arrows) in the interalveolar septa (Masson’s trichrome, x 200). b)section in the lung of a diabetic rat showing increased collagen fibers (arrows) in thickened interalveolar septa (Masson’s trichrome, x 200). c) section in the lung of a diabetic rat treated with curcumin showing less collagen fibers (arrows) in the interalveolar septa (Masson’s trichrome, x 200). d)section in the lung of a diabetic rat treated with SCs showing fine collagen fibers (arrows) in the interalveolar septa and around pulmonary capillaries (Masson’s trichrome, x 200).

Plate (4): a)section in the lung of a control rat showing negative staining among alveoli and alveolar sacs (Prussian blue, x400). b)section in the lung of a diabetic rat showing negative staining among alveoli, alveolar sacs and thickened interalveolar septa (Prussian blue, x400). c) section in the lung of a diabetic rat treated with curcum in showing negative staining among alveoli, alveolar sacs and less thickened interalveolar septa (Prussian blue, x400). d)section in the lung of a diabetic rat treated with SCs showing +ve staining of spindle cells (s) among alveoli, alveolar sacs and minimally thickened interalveolar septa (Prussian blue, x400).
DISCUSSION

The aim of the present study was designed to elucidate the possible ameliorative role of AMSCs and curcumin on the lung in STZ-induced type I diabetes of adult albino rat. Amelioration of diabetes induced changes in response to AMSCs and curcumin therapy was evidenced by histological, histochemical and immunohistochemical results and was confirmed by morphometric and biochemical results. Previous studies suggested that lung might be a target organ in type I diabetes, and its effect is either through direct effect or induction of inflammatory and fibrotic changes.

In the diabetic group, partial obliteration of the lumen, sometimes complete distortion of the bronchioles accompanied by thickening of the interalveolar septa were detected. These results were confirmed by a sig increase in the mean thickness of IAS. In accordance, obliterative bronchiolitis was due to bronchiolar wall injury by inflammatory cells and subsequently fibrous tissue proliferation[26]. Recently, inflammatory cell migration to the interalveolar and bronchoalveolar space is the key factor in the course of lung injury was recorded[27].

A sig increase in the mean thickness of the wall of the pulmonary vessels were noted in diabetic group compared to the other group. These changes might lead to pulmonary hypertension. In support, collagen deposition affects vascular remodelling due to the collagen ability and/or collagen binding macromolecules to sequester growth factors and cytokines into the extracellular matrix, which is the major constituent of the vessel wall[28].

Collagen fibers were increased in diabetic group compared to other groups; this confirmed by a sig increase in area % of CF. Concomitantly, a sig increase in STAT and SMAD genes. The pathogenesis of fibrosis and collagen deposition to transforming growth factor β1 (TGFβ1) which is a known cytokine that control the immune responses during inflammation was explained[29]. During lung fibrosis, TGFβ1 activates lung fibroblasts and promotes epithelial mesenchymal transformations of different cell types, such as alveolar type II cells. Studies have demonstrated the role of STAT pathway activation in patient with lung fibrosis. TGFβR1 forms a protein complex that activates STAT pathway via SMAD protein[30].

In the diabetic group a sig increase were found in
L-hyp level as compared to the control, L-hyp is an important biomarker for idiopathic pulmonary fibrosis (IPF). The most common method for evaluating tissue fibrosis and collagen deposition is hydroxyproline quantification. L-Hydroxyproline is a major component of collagen, comprising around 13.5% of its amino acid composition[31].

In the diabetic group, a sig decrease was found in the count of CD105+ve cells compared to the therapy groups. The previous finding might be related to a sig increase of MDA and TNF-α with a significant decrease of GSH and CAT. TNF-α in lungs is an indicator of pulmonary inflammation and fibrosis. It can be concluded that diabetes induced inflammatory changes and oxidative stress ending in fibrosis which indicates unfavourable niche of SCs. These results were in agreement with a previous histopathological study which reported that, initial elevation in cytokines such as TNF-α in lung, is followed by increased expression of the profibrotic cytokine TGF-β that induced a high oxidative stress and inflammation[32].

Regardless of cell origin and isolation technique, CD105 is a well-established MSC markers and indicating that they were of mesenchyme origin and specifically defined as ASC markers[33]. In the current work sig decrease in the count of CD105+ve cell in diabetic group compared to other group as mobilization of both stem cells and proangiogenic cells seems to be impaired in diabetics.

Concerning changes in curcumin treated group, it showed less thickening of the interalveolar septa compared to diabetic group with partial thickening of a vessel wall. Moreover, less dense infiltrating cells in the interalveolar septa were found with some normal alveoli and alveolar sacs. In support it was postulated that anti-diabetic activity of curcumin might be due to its potent ability to suppress oxidative stress and inflammation. Curcumin also modulates the advanced glycation end products-induced complications of diabetes and the levels of glycosylated hemoglobin in diabetic rat[34].

Morphological changes in curcumin group were confirmed biochemically by a sig decrease of MDA and sig increase of CAT and GSH compared to diabetic group. This improvement can be referred to its known antioxidant capacity. Additionally, curcumin attenuated TNFα that showed sig decrease compared to diabetic group while sig increase compared to AMSCs and control group.

Different cell signalling pathways activated by TNF have been shown to be down-regulated by curcumin one of these include PI3K/Akt pathway alteration. However, the mechanism by which curcumin mediates these anti-inflammatory effects in animals was not clear, but it was explained as curcumin blocked TNF production in cell culture and the expression of pro-inflammatory genes[35].

Minimal collagen fibers were detected in the IAS confirmed by a sig decrease in the mean area % of collagen fibers, in the mean thickness of pulmonary vessels wall and in the mean thickness of IAS compared to diabetic group. This demonstrates the antifibrotic role of curcumin which was in agreement with other authors, as they found that curcumin inhibit lung fibroblast proliferation and blocking transforming growth factor (TGF-β1) signalling cascade[36]. The role of curcumin as an antioxidant and anti-inflammatory agent on rat lung was studied and the authors added that curcumin increased tissue levels of proteases like cathepsin which in turn will prevent collagen accumulation in a murine model of bleomycin-induced pulmonary fibrosis[37].

A sig decrease in L-hyp level in curcumin group compared to diabetic group was detected in the current work, similarly, L-hyp content was studied in mice lung, and the authors concluded that L-hyp revealed a trend of decrease by approximately 10% after 21 days after curcumin therapy[38].

In AMSCs treated group, apparently normal alveoli, few shed epithelial cells in the lumen of some bronchioles, congested arterioles and venules were noticed. These results were confirmed by a sig decrease of the IAS and thickening of the wall of blood vessels compared to diabetic and curcumin groups. Mesenchymal stem cells are multipotent cells that can differentiate into different cell lines and have immunomodulatory, anti-proliferative, anti-fibrosis, anti-apoptosis, angiogenesis, growth factor production and anti-inflammatory effects. Their multipotency, migratory ability makes it the best therapeutic applications in chronic lung disease[39]. Increased vascularity and congestion with SCT are very essential factors in the equation of regeneration. The congestion and angiogenesis induced by AMSCs is associated with better tissue healing was proved[39].

In the present study the AMSCs treated group revealed a sig decrease of MDA and TNF-α while a sig increase of GSH and CAT as compared to the diabetic and curcumin groups. Early treatment with AMSCs may produce antagonists to TNF-α cytokines thus reduce the extent of lung inflammation as well as tissue healing by epithelial restoration[40]. These results were in agreement with the previous studies who stated that AMSCs decreased oxidative stress in the lung tissue and increased antioxidant activity as (GSH) by the secretion of soluble growth factors[39].
In AMSCs treated group, the collagen fibers were minimally detected in the IAS and around the pulmonary vessels compared to the diabetic and curcumin groups. This result was confirmed morphometrically by sig decrease in the mean area% of collagen fibers compared to other group that proved the benefit of AMSCs in the prevention of fibrosis. Going with, the early treatment with AMSCs is beneficial in prevention of lung fibrosis [40].

Multiple Prussian’s blue +ve cells were found around the congested blood vessels besides the thickened IAS. In agreement, following systemic administration of human ADSCs, they settled in the injured tissues of experimental rats [36]. This cell recruitment is essential for establishing beneficial effects of cell therapy, including enhanced functional and structural outcomes.

CONCLUSION

Diabetes induced inflammatory and fibrotic pulmonary changes that were ameliorated by curcumin therapy, and were more obviously ameliorated by AMSCs therapy.

CONFLICT OF INTEREST

There are no conflict of interests.

REFERENCES


34. Nabavi SF, Thiagarajan R, Rashedi L, Daglia M, Sobarzo-Sánchez E, Alimzad H, Nabavi


الملخص العربي

الدورالوقائي المحتمل للخلايا الجذعية والكركم على الرئة في داء السكري من النوع الأول المستحث تجريبياً: دراسة نسيجية ومناعية

أماني السيد محمد موسى حمودا1 - هالة جبر منتولي2

أقسام التشريح و الأتجة.1 الباثولوجيا الإكلينيكية والكيميائية
كلية الطب، جامعة القاهرة

المقدمة: داء السكري من النوع الأول يؤثر على الرئتين بسبب ضعف السيطرة على نسبة السكر في الدم. وقد وجد تحسن في كل من وظيفة الرئة والشكل العام للخلايا في إصابة الرئة الناجمة عن التحية التي تفتضي الجذعية بالخلايا الجذعية بواسطة أليات مختلفة. الكركم مضاد قوي للأكسدة ومضاد أيضا لتليف الرئة.

الهدف: تم تصميم الدراسة الحالية لتوضيح الدور الوقائى المحتمل للخلايا الجذعية والكركم على الرئة في داء السكري من النوع الأول المستحث تجريبياً من خلال دراسة نسيجية ومناعية.

الطرق والمواد المستخدمة: تم تقسيم ستة وعشرون من الفئران البالغة إلى خمس مجموعات، مجموعة المانحة، مجموعة الضابطة، مجموعة المصاب بالسكتري مع الخلايا الجذعية، مجموعة مصاب بالسكتري والكركم. مجموعة السكري تلقت جرعة واحدة 50 ملغ / كغم / يوم من عقار السكري. المجموعة الثالثة تلقت عقار السكري والكركم. المجموعة الرابعة تلقت عقار السكري والخلايا الجذعية. وفي نهاية التجربة، تم اجراء نسق عينة من الرئة وتم اعداد شرائح مجهرية وصبغها بالهيماتوكسلين والإليوزين، ومن ثم القياسات المورفومترية والكيميائية الحيوية والإحصائية.

النتائج: تسبب داء السكري في تغييرات نسيجية في الرئة في شكل تغييرات التهابية في القصيبات الهوائية، زيادة كبيرة في CD105، وفقدان الجملة. وتم رصد انخفاض ملحوظ في نشاط مضادات الأكسدة. زيادة ملحوظة في إنزيمات الأكسدة. زيادة ملحوظة في مستوى بعض الأنداميات وانخفاض ملحوظ في نشاط مضادات الأكسدة. وزيادة ملحوظة في إنزيمات الأكسدة. زيادة ملحوظة في مستوى بعض الأنداميات.

الاستنتاج: مرض السكري الناجم عن إصابات الرئة في الفئران التي تم تحسينها من قبل الكركم، ولكن الخلايا الجذعية تأثيرها أكثر واضحاً من علاج الكركم.